<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">
Go Back

Biodesix Names Douglas E. Swan, formerly of Imclone Systems Incorporated, as Vice President, Commercial Operations

Biodesix, Inc, announced today that Douglas E. Swan has joined the Company as Vice President, Commercial Operations, reporting directly to David Brunel, Chief Executive Officer. In this newly created position, Mr. Swan will be responsible for all commercial functions related to the marketing and sales of VeriStrat®. VeriStrat represents the company’s first diagnostic test which is a simple blood test that provides additional information to oncologists treating non-small cell lung carcinoma (NSCLC) during their decision making process.

Mr. Swan has served in sales and marketing positions for over 25 years at companies including ImClone Systems, Baxter Healthcare and Genentech Inc. In his most recent position at ImClone, Mr. Swan served as Vice President, Field Operations from 2003 to 2007. Prior to joining ImClone, Mr. Swan served as the Vice President, North America Sales and Marketing at Baxter Healthcare and Director of Marketing at Genentech Inc., where he was responsible for the launch of monoclonal antibody therapies targeting non-Hodgkin’s lymphoma and breast cancer.

“The addition of Doug to lead our commercial efforts marks another step in the development of Biodesix as a fully integrated diagnostics company. Doug is a proven leader in the area of sales, marketing and reimbursement and was instrumental in the launch of two of the most important monoclonal antibody therapeutics for the treatment of cancer. His record also attests to his ability to market and sell products while working closely with teams from partner companies.”

About Biodesix

Biodesix is a fully integrated molecular diagnostic company enabling personalized health care using mass spectrometry-based molecular profiling. Working with academic and biopharma collaborators, Biodesix uses its proprietary technology, ProTS® to discover and validate diagnostic tests that improve patient outcomes. Biodesix’ first product, VeriStrat, is commercially available for physicians to help guide their treatment of patients with non-small cell lung cancer. For more information on Biodesix, visit www.Biodesix.com.

This press release contains statements that are hereby identified as “forward-looking statements” for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the Company’s inability to further identify, develop and achieve commercial success for products and technologies; the risk that the Company’s financial resources will be insufficient to meet the Company’s business objectives; uncertainties relating to the regulatory approval process and changes in relationships with strategic partners. We disclaim any intent or obligation to update these forward-looking statements.

Topics: blood-based cancer test, cancer diagnostics, personalized medicine, Press Releases, lung cancer, molecular diagnostic, Non-Small Cell Lung Cancer, NSCLC, oncology